Business Context and Reporting Period
Company: Rambus Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Rambus develops and licenses chip interface technologies (memory and logic) to improve semiconductor performance. Revenue is derived primarily from royalties on patented inventions and contract revenues (license fees and engineering services). The company operates in a single reportable segment with significant international exposure (69% of revenue).
Key Financial Metrics (Year Ended Dec 31, 2004)
| Metric | 2004 (in millions) | 2003 (in millions) |
|---|---|---|
| Total Revenues | $144.9 | $118.2 |
| Operating Income | $39.5 | $27.3 |
| Net Income | $33.6 | $23.2 |
| Diluted EPS | $0.30 | $0.22 |
| Cash from Operations | $43.7 | $23.4 |
| Cash & Marketable Securities | $236.4 | $166.5 |
| Total Debt | $0 | $0 |
Note: Debt figures reflect the balance sheet as of Dec 31, 2004. A subsequent debt issuance occurred in Feb 2005 (see below).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 22.6% to $144.9 million. This was driven by a 59% increase in contract revenues ($24.8M vs $15.6M) due to XDR, FlexIO, and RaSer interface contracts, and a 17% increase in royalties ($120.1M vs $102.6M) primarily from SDRAM/DDR-compatible products.
- Profitability: Operating margin improved to 27.3% from 23.1% in 2003. Net income rose 44.5% to $33.6 million.
- Expense Trends:
- Engineering Costs: Increased 14.3% to $52.9 million due to hiring, amortization of acquired IP (Velio and Cadence), and patent filing costs.
- Marketing, G&A: Increased 17.7% to $52.5 million, largely due to higher litigation expenses ($23.1M vs $20.4M) and corporate governance costs.
- Customer Concentration: Top five customers accounted for 74% of revenue. Intel, Toshiba, and Elpida each contributed over 10% of total revenue.
Guidance, Outlook, Risks, and Unusual Items
Subsequent Events (Post-Dec 31, 2004)
- Debt Issuance: On Feb 1, 2005, Rambus issued $300 million in zero-coupon senior convertible notes due 2010. Net proceeds were approximately $293 million.
- Stock Repurchase: On Jan 27, 2005, the company repurchased 4.1 million shares for $75 million in connection with the note issuance.
Management Commentary & Outlook
- Revenue Recognition: Contract revenues for XDR, FlexIO, and RaSer are recognized using the percentage-of-completion method, creating volatility based on project progress.
- License Expirations: All but one SDRAM/DDR license agreement expires in 2005. Renewal is critical for future revenue stability.
- Tax Rate: Effective tax rate was 30% in 2004; management expects a rate of 37% in 2005.
Material Risks & Contingencies
- Infineon Litigation: A retrial is scheduled for early 2005. Infineon has raised "unclean hands" and spoliation defenses. Management believes an unfavorable outcome is probable and could lead to significant stock price decline, loss of patent rights, or inability to collect royalties.
- FTC & European Patent Office: The FTC has appealed an initial decision dismissing its complaint against Rambus. Additionally, the EPO revoked a key European patent (EP 004956) in Jan 2005, leaving only one issued patent in Europe for DDR products pending appeal.
- Intel Dependency: Intel is the largest customer. The patent cross-license agreement expires in Sept 2006, after which Intel holds a paid-up license for pre-2006 patents.
- Accounting Changes: Adoption of SFAS 123R (Share-Based Payment) in 2005 will require expensing stock options, which could materially reduce reported net income.
Investor Verification Checklist
- Infineon Trial Outcome: Monitor the Feb/March 2005 bench and jury trials regarding spoliation and patent infringement, as this poses an existential threat to the royalty model.
- License Renewals: Verify the status of SDRAM/DDR license renewals due in 2005, particularly with top customers Intel, Toshiba, and Elpida.
- Convertible Note Terms: Review the conversion price ($26.84) and potential dilution from the $300M note issuance.
- European Patent Status: Track the appeal of the revoked European Patent EP 004956, which impacts enforcement in a key market.
- Stock-Based Compensation Impact: Assess the pro-forma impact of SFAS 123R adoption on 2005 earnings, as reported net income may not reflect future cash costs.